Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Geron, Merck deal

July 25, 2005 7:00 AM UTC

The companies will use GERN's telomerase technology with MRK's vaccine platform to develop a cancer vaccine targeting telomerase. GERN will receive an upfront payment and is eligible for milestones a...